Panacea Biotec Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts less than Nifty Microcap 250 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Panacea Biotec has filed its unaudited financial results for the quarter and half-year ended September 30, 2025 with the stock exchanges. This is a routine regulatory disclosure following the end of the quarter. The detailed figures on revenue, profit/loss, margins, and other line items are not contained in the filing excerpt provided. Investors will need to refer to the full results document or PDF on the NSE/BSE portal to evaluate the company's actual performance.
On its own, the submission notice is a procedural filing and typically does not move the stock. The real impact will depend on the numbers inside the results — investors should review the full quarterly financials, especially revenue trajectory and bottom-line performance, to gauge whether the company is improving from prior periods.